ABSTRACT Randomized controlled trials remain the cornerstone of evidence generation in amyotrophic lateral sclerosis (ALS), yet their inherent challenges, including disease rarity, heterogeneity, and limited validated biomarkers, highlight the need for complementary clinical evidence. This exploratory, retrospective study assessed overall survival in patients with ALS treated with intravenous (IV) edaravone using data from a large United States administrative claims database of patients enrolled from August 2017 to March 2020. Patients receiving IV edaravone ( n = 318) were propensity score matched 1:1 with controls not treated with IV edaravone ( n = 318), adjusting for 11 covariates. Median overall survival was 29.5 versus 23.5 months for the edaravone‐treated group compared to controls, with a 27% reduced risk of death observed in the treated cohort ( p = 0.005). These findings, together with existing data from the pivotal phase 3 Study MCI186‐19 of IV edaravone, contribute to the growing body of literature suggesting a dual benefit of edaravone on both function and survival in ALS, offering critical insights for clinicians, patients, and payers navigating ALS treatment decisions.
Brooks et al. (2026) studied this question.